Article
A mutation of cysteine 46 in IKK-β promotes mPGES-1 and caveolin-1 expression to exacerbate osteoclast differentiation and osteolysis.
Biochemical pharmacology - 1 Feb 2020
Zou Binhua, Zhang Yueyang, Li Ting, Liu Juan, Deng Wende, Tan Yanhui, Yang Qin, Ding Zongbao, Liao Kangsheng, Xu Jialan, Pan Hudan, Li Xiaojuan, Liu Liang
Abstract excerpt
IKK-β is indispensable for inflammatory osteolysis, the functional residues of IKK-β are therapeutic drug targets for developing inhibitors to treat multiple diseases now. Thus it remains appealing to find the new residues of IKK-β to influence osteoclasts for alleviating bone loss diseases such as rheumatoid arthritis (RA). By employing IKK-β cysteine 46-A transgenic (IKK-βC46A) mice, we found that mutation of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
